PAR GENERIC OM3 JUST APPROVED

Quote






Anonymous said:
See FDA Website... is it shipping in near future? There goes the apple cart.
Click to expand...

Okay, we'll let GSK and Teva know the bad news as they are purveyors of at least 900MG of the ETHYL ESTERS OF OMEGS-3 FATTY ACIDS. AZN might want to know too since Epanova is essentially the same thing.

Vascepa, on the other hand, is the sole purveyor of 1GM of ICOSAPENT ETHYL. No worries here!
 






Another formulary genius. EPA is really denting the OM3 market. Teva is perpetually sold out at 45% of the market, increasing capacity and Par on stream by the Fall = market price craters.
 






Amarin friends you have two choices:

1. Accept the inevitable step-edit and generic failuresand possibly get a few physicians to fight for the LDL challenged patients, but when they are incentivized or told by their bosses to do otherwise, well, welcome to 2014 medicine.
2. Contract with deep discounts to continue favored status and make it up with huge market share gains.

You can see neither can you win because with number one, your growth is completely stifled and since tg is not a "life threatening" issue in the minds of most prescribers today....

With number two, Amarin and Kowa have shown the inability to move the market share anywhere close to being profitable in this model.

You are between a rock and a hard place of reality. I am not GSK by the way. I am a realist.

Sorry.

That's it, there is nothing else you can do.
 












Top Bottom
Back
Quote